CY1106643T1 - Αναστολεις συνθεσης βλεννινης - Google Patents

Αναστολεις συνθεσης βλεννινης

Info

Publication number
CY1106643T1
CY1106643T1 CY20071100747T CY071100747T CY1106643T1 CY 1106643 T1 CY1106643 T1 CY 1106643T1 CY 20071100747 T CY20071100747 T CY 20071100747T CY 071100747 T CY071100747 T CY 071100747T CY 1106643 T1 CY1106643 T1 CY 1106643T1
Authority
CY
Cyprus
Prior art keywords
mucine
synthesis inhibitors
diseases
chronic
mucus
Prior art date
Application number
CY20071100747T
Other languages
English (en)
Inventor
Yuhong Zhou
Roy C. Levitt
Nicholas C. Nicolaides
Steve Jones
Mike Mclane
Original Assignee
Genaera Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corporation filed Critical Genaera Corporation
Publication of CY1106643T1 publication Critical patent/CY1106643T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η αξιωθείσα εφεύρεση αναφέρεται σε μεθόδους ρύθμισης της σύνθεσης βλεννίνης και στην θεραπευτική εφαρμογή ενώσεων για τον έλεγχο της υπερπαραγωγής της βλεννίνης, η οποία σχετίζεται με ασθένειες όπως είναι τα χρόνια αποφρακτικά νοσήματα των πνευμόνων (COPD), περιλαμβάνοντας το άσθμα και την χρόνια βρογχίτιδα, τα φλεγμονώδη νοσήματα των πνευμόνων, την κυστική ίνωση και τα οξεία ή χρόνια μολυσματικά νοσήματα.
CY20071100747T 2000-01-31 2007-06-05 Αναστολεις συνθεσης βλεννινης CY1106643T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17912700P 2000-01-31 2000-01-31
US19311100P 2000-03-30 2000-03-30
US23078300P 2000-09-07 2000-09-07
US24213400P 2000-10-23 2000-10-23
US25205200P 2000-11-20 2000-11-20
PCT/US2001/003078 WO2001054685A1 (en) 2000-01-31 2001-01-31 Mucin synthesis inhibitors

Publications (1)

Publication Number Publication Date
CY1106643T1 true CY1106643T1 (el) 2012-01-25

Family

ID=27539006

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100747T CY1106643T1 (el) 2000-01-31 2007-06-05 Αναστολεις συνθεσης βλεννινης

Country Status (13)

Country Link
US (2) US6737427B2 (el)
EP (1) EP1255544B1 (el)
JP (1) JP2004507444A (el)
AR (1) AR042578A1 (el)
AT (1) ATE355836T1 (el)
AU (2) AU3467101A (el)
CA (1) CA2398642A1 (el)
CY (1) CY1106643T1 (el)
DE (1) DE60127098T2 (el)
DK (1) DK1255544T3 (el)
ES (1) ES2282235T3 (el)
PT (1) PT1255544E (el)
WO (1) WO2001054685A1 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147216A1 (en) * 2000-01-31 2002-10-10 Yuhong Zhou Mucin synthesis inhibitors
DE60127098T2 (de) * 2000-01-31 2007-11-29 Genaera Corp. Inhibitoren der mucin-synthese
US7345051B2 (en) * 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
US8474460B2 (en) 2000-03-04 2013-07-02 Pulmonx Corporation Implanted bronchial isolation devices and methods
US20030059434A1 (en) * 2000-08-09 2003-03-27 Andrew Grupe Methods and compositions for treating gastrointestinal tract mucin production associated disease conditions
US20030050648A1 (en) 2001-09-11 2003-03-13 Spiration, Inc. Removable lung reduction devices, systems, and methods
US6592594B2 (en) 2001-10-25 2003-07-15 Spiration, Inc. Bronchial obstruction device deployment system and method
US6818446B2 (en) 2001-11-21 2004-11-16 The Regents Of The University Of California Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression
US20030216769A1 (en) 2002-05-17 2003-11-20 Dillard David H. Removable anchored lung volume reduction devices and methods
US20030181922A1 (en) 2002-03-20 2003-09-25 Spiration, Inc. Removable anchored lung volume reduction devices and methods
EP1524942B1 (en) 2002-07-26 2008-09-10 Emphasys Medical, Inc. Bronchial flow control devices with membrane seal
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
CN1829526A (zh) 2003-05-28 2006-09-06 惠氏公司 可溶性clca－1及clca－1的拮抗剂
JP2007524618A (ja) * 2003-06-19 2007-08-30 ジェネーラ・コーポレーション ムチン合成阻害剤
US7533671B2 (en) 2003-08-08 2009-05-19 Spiration, Inc. Bronchoscopic repair of air leaks in a lung
EP1773405A4 (en) * 2004-07-22 2011-10-05 Duska Scient Co METHOD FOR DIAGNOSIS, MONITORING AND TREATMENT OF LUNG DISEASES
US7771472B2 (en) 2004-11-19 2010-08-10 Pulmonx Corporation Bronchial flow control devices and methods of use
WO2006061414A1 (en) * 2004-12-09 2006-06-15 Ingenium Pharmaceuticals Ag Methods and agents useful in treating conditions characterized by mucus hyperproduction/ hypersecretion
WO2006075172A2 (en) * 2005-01-13 2006-07-20 University Of Dundee Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2
US8876791B2 (en) 2005-02-25 2014-11-04 Pulmonx Corporation Collateral pathway treatment using agent entrained by aspiration flow current
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
EP2043603A4 (en) 2006-07-11 2010-10-27 Arubor Corp PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
HUE048024T2 (hu) 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
US20100166726A1 (en) * 2007-03-07 2010-07-01 Northeastern University Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation
EP2641572B1 (en) 2007-10-12 2019-07-24 Spiration Inc. Valve loader method, system, and apparatus
GB0905954D0 (en) * 2009-04-06 2009-05-20 E Therapeutics Plc Treatment of exacerbations of asthma
CA2797033C (en) * 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2012134965A1 (en) * 2011-03-25 2012-10-04 The Trustees Of Columbia University In The City Of New York Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases
EP2758010B1 (en) 2011-09-23 2017-02-08 Pulmonx, Inc Implant loading system
EP2968469A4 (en) 2013-03-15 2016-08-31 Longevity Biotech Inc PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
WO2015182565A1 (ja) * 2014-05-27 2015-12-03 リンク・ジェノミクス株式会社 肺疾患治療剤
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4168313A (en) * 1978-02-21 1979-09-18 Sebastian Bago Phthalidyl 2-(3'-trifluoromethyl-anilino)-pyridine-3-carboxylate and its salts
US4515980A (en) * 1983-07-11 1985-05-07 Sterling Drug Inc. Substituted aminobenzoates, their preparation and use
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4666716A (en) * 1984-09-04 1987-05-19 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
DE3682136D1 (de) * 1985-07-31 1991-11-28 Hoechst Ag N-substituierte 5-nitroanthranilsaeuren, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen.
DE3608726A1 (de) * 1986-03-15 1987-09-17 Hoechst Ag Verwendung aminosubstituierter benzoesaeuren als heilmittel gegen diarrhoe und arzneimittel auf basis dieser verbindungen
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
WO1996039419A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Colon specific genes and proteins
DE29680627U1 (de) * 1995-07-20 1999-06-02 Juergens, Uwe R., Dr.med., 53859 Niederkassel Nicht-steroidales Antiphlogistikum zur topischen und systemischen Behandlung der akuten und chronischen polypoiden Rhinosinusitis
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
NZ336659A (en) * 1997-01-08 2001-01-26 Upjohn Co Pharmaceutically active pyrimido[4,5-b]indoles
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
ATE344791T1 (de) * 1997-07-01 2006-11-15 Warner Lambert Co 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
AU2674399A (en) * 1998-02-11 1999-08-30 Regents Of The University Of California, The Compositions and methods for the inhibition of muc-5 mucin gene expression
US6576434B1 (en) * 1998-03-03 2003-06-10 Genaera Corporation Methods for identification of agents which modulate chloride channel activity
WO2000040235A2 (en) * 1999-01-07 2000-07-13 Warner-Lambert Company Treatment of asthma with mek inhibitors
AU2201500A (en) * 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
SK9822001A3 (en) * 1999-01-13 2002-08-06 Warner Lambert Co 1-heterocycle substituted diarylamines, pharmaceutical compositions based thereon and their use in therapy
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
AU7965000A (en) * 1999-09-27 2001-04-30 Jun-Suk Oh Use of analgesics as digestive and medicines for expectorating and transdermal therapeutic system using the same
DE60127098T2 (de) * 2000-01-31 2007-11-29 Genaera Corp. Inhibitoren der mucin-synthese
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
AR042578A1 (es) 2005-06-29
US6737427B2 (en) 2004-05-18
EP1255544A4 (en) 2005-02-02
JP2004507444A (ja) 2004-03-11
AU2001234671B2 (en) 2006-05-18
CA2398642A1 (en) 2001-08-02
ATE355836T1 (de) 2007-03-15
ES2282235T3 (es) 2007-10-16
EP1255544A1 (en) 2002-11-13
US20010041685A1 (en) 2001-11-15
EP1255544B1 (en) 2007-03-07
WO2001054685A1 (en) 2001-08-02
DE60127098D1 (de) 2007-04-19
DK1255544T3 (da) 2007-09-17
DE60127098T2 (de) 2007-11-29
PT1255544E (pt) 2007-06-15
US20040254096A1 (en) 2004-12-16
US7504409B2 (en) 2009-03-17
AU3467101A (en) 2001-08-07

Similar Documents

Publication Publication Date Title
CY1106643T1 (el) Αναστολεις συνθεσης βλεννινης
SE0200356D0 (sv) Novel use
NO20061254L (no) Farmasoytiske blandinger
IS6444A (is) Pýrimidín karboxamíð nytsamleg sem latar á PDE4 samsætuensím
CY1118171T1 (el) Θεραπευτικη αντιμετωπιση της φαiνυλκετονουρiας me βη4
NO20051726L (no) Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
CY1109712T1 (el) Φαρμακευτικες συνθεσεις με βαση τιοτροπιο, κικλεσονιδη και ενα βητα μιμητικο για τη θεραπεια φλεγμονωδων και/ή αποφρακτικων παθησεων των αναπνευστικων οδων
CY1106027T1 (el) 2,5-διοξοϊμιδαζολιδιν-4-υλ ακεταμιδια και αναλογα ως αναστολεις μεταλλοπρωτεϊνασης μμρ12
DK1718336T3 (da) Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
EA200700037A1 (ru) Производные n-гидроксиамида и их применение
HUP0300570A2 (hu) Cestrum sárga levélfodrosodás vírus promóterek
ATE534630T1 (de) Sulfonamidderivate und deren verwendung zur modulation von metalloproteinasen
WO2004113286A3 (en) Mucin synthesis inhibitors
NO975028D0 (no) Piperazinoderivater som neurokininantagonister
EA200100515A2 (ru) Диазепиноиндолы для лечения хронического обструктивного заболевания легких
BRPI0516383A (pt) derivados cìclicos de sulfonil amino e o uso dos mesmos
BG106748A (en) Method and compositions for treating pulmonary diseases
SE9900834D0 (sv) Novel combination
CY1105855T1 (el) Μεθοδος παραγωγης μοριων ανασυνδυασμενου dna
WO2003011294A3 (en) Mucin synthesis inhibitors
FI965097A (fi) Substituoidut alkyylidiamiinijohdannaiset ja niiden käyttö takykiniini antagonisteina
ATE323505T1 (de) Verwendung von rekombinantem lungensurfactant zur frühbehandlung von akuten lungenerkrankungen
DK1844032T3 (da) N-hydroxyamid-derivater og deres anvendelse
NO965099D0 (no) Acylerte enolderivater som prolegemidler av elastaseinhibitorer
DE602005023874D1 (de) Octahydropyrroloä2, 3, cüpyridinderivative und pharmazeutische verwendung damit